Protective effect of inhaled salbutamol powder in children assessed by histamine challenge

C R PULLAN, A J MARTIN

Summary and conclusions
A double-blind placebo-controlled trial of 100, 400, and 800 μg inhaled salbutamol powder was conducted on 12 children. The protective effect at 10 minutes, two hours, and four hours was assessed by histamine challenge. At 10 minutes there was good protection with all doses, but by four hours there was significant protection only with 800 μg (p <0·01). Salbutamol powder may need to be taken at least every four hours for complete protection. There was a dose-related effect with a single dose of up to 800 μg; increasing the dose increased the effect and duration of action.

Currently advertised dose regimens of salbutamol powder for children (200 μg three or four times a day) are apparently submaximal. Histamine challenge is a satisfactory method of assessing the protective effect of a drug in asthmatic children.

Introduction
Inhaled salbutamol is well established as a valuable treatment of wheezing in children. Many young children have difficulty mastering the metered aerosol but can use a dry powder inhaler. Young children unable to use a metered aerosol who require inhaled salbutamol have to use air compressors to drive nebulisers, which are both cumbersome and expensive.

Salbutamol powder is now available for use in an inhaler (Rotahaler, Allen and Hanbury's). This effectively increases the forced expiratory volume in one second (FEV₁) in adults and children. The recommended prophylactic dose is 400 μg for adults and 200 μg for children three or four times a day. This dose, however, may produce submaximal responses in children, and Hetzel and Clark reported increasing effect in adults with cumulative doses of up to 800 μg. Many children with asthma have intermittent wheezing with a normal FEV₁ for much of the time. Hence testing a single dose of a drug and its effect on FEV₁ can be done only on a few more severely affected children. In the other cases, however, episodes may still be frequent enough to warrant continuous treatment with salbutamol.

Histamine is a non-specific bronchoconstrictor in increased bronchial lability. It is useful in assessing the protective effect of drugs, since the bronchoconstriction can be controlled and its effect is transient. We decided to assess the protective effect of a single dose of salbutamol powder using inhaled histamine. The trial was approved by the local ethical committee.

Subjects and methods
Twelve children aged 6-13 years with episodic asthma were studied. All could perform satisfactory forced expiratory manoeuvres. Eleven had a baseline FEV₁ of 70% or more of the predicted normal value on each day (normal values taken from Cogswell et al.) One boy had an FEV₁ of 58%, predicted on one day and between 70% and 90% on the other days. Only steroids were continued from 12 hours before the start of each study day until after the last histamine challenge of that day.

Histamine challenge—The histamine challenge procedure used was similar to that of Chai et al. FEV₁ was recorded on a Vitalsograph. When consistent results were obtained the best of three was used as a baseline. Buffered histamine acid phosphate was used in roughly doubling concentrations from 0·03 mg/ml to 10 mg/ml. Solutions were administered by facemask from a Bard Mini-Neb nebuliser driven by oxygen at 8 l/min. Five inspiratory capacity breaths were taken first of diluent alone, and three minutes later the FEV₁ was recorded. Provided there was no fall in FEV₁ with the diluent this was repeated with increasing concentrations of histamine at four-minute intervals until the FEV₁ had fallen by 20% or more. The test was then stopped. The concentration of histamine that would produce a 20% fall (provocation concentration 20; PC₂₀) was calculated from the dose-response curve. If the FEV₁ did not fall by 20% with the top concentration (10 mg/ml) a PC₁₀ was calculated by extrapolation up to 20 mg/ml but not beyond.

We acknowledge the help and encouragement of the British Diabetic Association and the helpful co-operation of the Ames, Boehringer, Hypoguard, and Medistar companies.

References

(Accepted 15 November 1979)
Salbutamol powder trial—Each of the 12 children was studied on four separate days within two weeks. Salbutamol and placebo cartridges were administered by Rotahaler in the following combinations: (1) placebo + placebo, (2) placebo + 100 μg, (3) placebo + 400 μg, (4) 400 μg + 400 μg. Cartridges were given double-blind in an order determined by the Latin-square design. A baseline histamine challenge was carried out at 9 am each day and the PC<sub>20</sub> established. The cartridges were given two hours later. Histamine challenge was repeated at 10 minutes, two hours, and four hours after administration of the cartridges and a new value for PC<sub>20</sub> obtained. Pulse rate was taken before and 10 minutes after the cartridges were given.

Statistical—The increase from baseline of log<sub>10</sub> PC<sub>20</sub> was calculated and significance of differences between doses estimated by paired t tests.

Results

Eight children had a baseline PC<sub>20</sub> that remained within three consecutive concentrations of histamine solution, but three children varied by four concentrations and one by five. There was no statistically significant difference between the mean baselines for all 12 children with each dose (p > 0.2). During the day when placebo was given the PC<sub>20</sub> with the baseline challenge was close to that of the last challenge of the day; 11 children varied by one concentration and one by two concentrations.

The figure shows the mean increase from baseline log<sub>10</sub> PC<sub>20</sub> in all 12 children with each dose at each time. At 10 minutes all salbutamol doses showed significantly better protection than placebo (100 μg p < 0.05; 400 μg p < 0.005); 800 μg p < 0.005). At two hours there was still significant protection with all doses (100 μg p < 0.02; 400 μg p < 0.005; 800 μg p < 0.005), but there was a trend for enhanced protection with higher doses (100 μg v 400 μg p > 0.2; 400 μg v 800 μg p > 0.01; but 100 μg v 800 μg p < 0.02). By four hours there was no significant protection with 100 μg (p > 0.02) or 400 μg (p > 0.05), but there was with 800 μg (p < 0.01).

The increase in mean pulse rate after placebo was 4.0 (range 8 to +16) beats/min, and after 100 μg 3.5 (range 12 to +24) beats/min. Neither of these rises was significant. Mean pulse rate increased by 7.4 (range 0 to +24) beats/min 10 minutes after 400 μg salbutamol (p < 0.05) and by 9.5 (range 4 to +24) beats/min after 800 μg (p < 0.05).

Discussion

Salbutamol dry powder effectively raised the threshold of sensitivity to histamine challenge. A pilot study on seven children showed significant difference between 200 μg and 400 μg at 30 minutes, three hours, and six hours, so 100 μg was chosen to see if it was equally effective and 800 μg to investigate the possibility of a greater effect with higher doses.

All doses of salbutamol gave satisfactory protection at 10 minutes. Some discrimination between the doses was lost because several children had a PC<sub>20</sub> exceeding 20 mg/ml, but all these were counted as 20 mg/ml. There was a definite though small placebo response at 10 minutes, but this had disappeared at two hours. The benefit of the larger doses was seen in their duration of action. There was evidence of a dose-related effect, though the difference between only 100 and 800 μg reached significance. By four hours only 800 μg gave significant protection. This suggests that higher doses may benefit some children who get suboptimal or brief benefit from the standard dose. Although the mean pulse rate increased after 400 and 800 μg, this never caused concern and there were no subjective side effects. We have no information on side effects with regular use of higher doses.

Although some protection against histamine-induced bronchoconstriction remained at four hours with 800 μg, it was much reduced. Children who require regular treatment with salbutamol powder may need to take it at least every four hours.

Histamine challenge was well tolerated by all children. The fall in FEV<sub>1</sub> was generally between 20% and 30%, and any tightness in the chest was gone within 10-20 minutes. There was baseline variability, but there was no evidence of a cumulative effect or tolerance when histamine challenge was repeated every two hours. Sensitivity to histamine is consistent in adults over a short period<sup>18</sup> but may vary with season<sup>12</sup> and time of day.<sup>14</sup> Histamine challenge therefore constituted a useful method of assessing the response of asthmatic children to the protective effect of a drug and its duration of action.

References


(Accepted 20 November 1979)